Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study.

IF 2.2 4区医学 Q3 RHEUMATOLOGY

Scandinavian Journal of Rheumatology Pub Date : 2025-05-01 Epub Date: 2025-03-03 DOI:10.1080/03009742.2025.2467556

A Kim, S C Kim, J Kim, M W So, S-G Lee

{"title":"Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study.","authors":"A Kim, S C Kim, J Kim, M W So, S-G Lee","doi":"10.1080/03009742.2025.2467556","DOIUrl":null,"url":null,"abstract":"Objective: To compare the risk of cardiovascular disease (CVD) and gastrointestinal bleeding (GIB) between celecoxib and non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) in patients with ankylosing spondylitis (AS).Method: In this nationwide retrospective cohort study using the Korean Health Insurance Review and Assessment database, adult AS patients who received newly prescribed non-steroidal anti-inflammatory drugs (NSAIDs) continuously for ≥ 30 days (celecoxib or nsNSAIDs) between 2013 and 2017 were evaluated. The co-primary outcomes were the occurrence of composite CVD events, including hospitalization for myocardial infarction, ischaemic heart disease, stroke, transient ischaemic attack, heart failure, and coronary revascularization; and composite GIB, including hospitalization for upper and lower GIB. Propensity score (PS) matching was used to correct for baseline differences between the celecoxib- and nsNSAID-treated groups.Results: We identified 3164 celecoxib-treated and 18924 nsNSAID-treated patients with AS. After 1:1 PS matching, 3047 patients with AS were assigned to each of the celecoxib- and nsNSAID-treated groups. The incidence of composite CVD and GIB was 18.2/1000 person-years and 6.5/1000 person-years in celecoxib-treated and 15.1/1000 person-years and 7.3/1000 person-years in nsNSAID-treated patients, respectively. Compared to the nsNSAID-treated group, the hazard ratios of composite CVD and GIB in the celecoxib-treated group were not significant, with values of 1.17 (p = 0.499) and 0.87 (p = 0.696), respectively. There were no significant differences in the risk of each component of the composite CVD and GIB between the two groups.Conclusion: We did not find significant differences in the risks of CVD and GIB between celecoxib and nsNSAIDs in AS patients.","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"204-212"},"PeriodicalIF":2.2000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03009742.2025.2467556","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To compare the risk of cardiovascular disease (CVD) and gastrointestinal bleeding (GIB) between celecoxib and non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) in patients with ankylosing spondylitis (AS).

Method: In this nationwide retrospective cohort study using the Korean Health Insurance Review and Assessment database, adult AS patients who received newly prescribed non-steroidal anti-inflammatory drugs (NSAIDs) continuously for ≥ 30 days (celecoxib or nsNSAIDs) between 2013 and 2017 were evaluated. The co-primary outcomes were the occurrence of composite CVD events, including hospitalization for myocardial infarction, ischaemic heart disease, stroke, transient ischaemic attack, heart failure, and coronary revascularization; and composite GIB, including hospitalization for upper and lower GIB. Propensity score (PS) matching was used to correct for baseline differences between the celecoxib- and nsNSAID-treated groups.

Results: We identified 3164 celecoxib-treated and 18924 nsNSAID-treated patients with AS. After 1:1 PS matching, 3047 patients with AS were assigned to each of the celecoxib- and nsNSAID-treated groups. The incidence of composite CVD and GIB was 18.2/1000 person-years and 6.5/1000 person-years in celecoxib-treated and 15.1/1000 person-years and 7.3/1000 person-years in nsNSAID-treated patients, respectively. Compared to the nsNSAID-treated group, the hazard ratios of composite CVD and GIB in the celecoxib-treated group were not significant, with values of 1.17 (p = 0.499) and 0.87 (p = 0.696), respectively. There were no significant differences in the risk of each component of the composite CVD and GIB between the two groups.

Conclusion: We did not find significant differences in the risks of CVD and GIB between celecoxib and nsNSAIDs in AS patients.

查看原文本刊更多论文

一项全国性的回顾性队列研究表明，在强直性脊柱炎患者中，塞来昔布和非选择性非甾体类抗炎药的心血管疾病和胃肠道出血风险相当。

目的：比较塞来昔布与非选择性非甾体抗炎药（nsnsaaids）治疗强直性脊柱炎（AS）患者发生心血管疾病（CVD）和胃肠道出血（GIB）的风险。方法：在这项使用韩国健康保险审查和评估数据库的全国性回顾性队列研究中，对2013年至2017年期间连续服用新开非甾体类抗炎药(nsaid)≥30天（塞来昔布或nsnaids）的成年AS患者进行评估。共同主要结局是复合CVD事件的发生，包括因心肌梗死、缺血性心脏病、中风、短暂性缺血发作、心力衰竭和冠状动脉血运重建术住院；综合免疫，包括上、下免疫的住院治疗。倾向评分（PS）匹配用于纠正塞来昔布和nsnsaid治疗组之间的基线差异。结果：我们确定了3164例塞来昔布治疗的AS患者和18924例nsnsaid治疗的AS患者。1:1 PS匹配后，3047例AS患者被分配到塞来昔布和nsnsaid治疗组。塞来昔布治疗组复合CVD和GIB的发生率分别为18.2/1000人年和6.5/1000人年，nsnsaid治疗组分别为15.1/1000人年和7.3/1000人年。与nsnsaid治疗组相比，塞来昔布治疗组复合CVD和GIB的风险比均无统计学意义，分别为1.17 （p = 0.499）和0.87 （p = 0.696）。两组间复合心血管疾病和GIB各组成部分的风险无显著差异。结论：我们未发现塞来昔布和非甾体抗炎药在AS患者CVD和GIB风险方面存在显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Scandinavian Journal of Rheumatology 医学-风湿病学

CiteScore

3.70

自引率

4.80%

发文量

审稿时长

6-12 weeks

期刊介绍： Scandinavian Journal of Rheumatology is the official journal of the Scandinavian Society for Rheumatology, a non-profit organization following the statutes of the Scandinavian Society for Rheumatology/Scandinavian Research Foundation. The main objective of the Foundation is to support research and promote information and knowledge about rheumatology and related fields. The annual surplus by running the Journal is awarded to young, talented, researchers within the field of rheumatology.pasting The Scandinavian Journal of Rheumatology is an international scientific journal covering clinical and experimental aspects of rheumatic diseases. The journal provides essential reading for rheumatologists as well as general practitioners, orthopaedic surgeons, radiologists, pharmacologists, pathologists and other health professionals with an interest in patients with rheumatic diseases. The journal publishes original articles as well as reviews, editorials, letters and supplements within the various fields of clinical and experimental rheumatology, including; Epidemiology Aetiology and pathogenesis Treatment and prophylaxis Laboratory aspects including genetics, biochemistry, immunology, immunopathology, microbiology, histopathology, pathophysiology and pharmacology Radiological aspects including X-ray, ultrasonography, CT, MRI and other forms of imaging.